[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-hypertension":59},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,86,111,135,159,182,204],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100639936","the-effect-of-self-acupressure-on-blood-pressure-stress-and-well-being-levels-in-individuals-with-hypertension-100639936",false,"NCT07577973","The Effect of Self-Acupressure on Blood Pressure, Stress, and Well-Being Levels in Individuals With Hypertension","The Effect of Self-Acupressure on Blood Pressure, Stress, and Well-Being Levels in Individuals With Hypertension: A Three-Arm Randomized Controlled Trial","SAPH","Inclusion Criteria:\n\n1. Aged 18-65 years\n2. Diagnosed with primary hypertension (Stage 1 or 2)\n3. Systolic blood pressure 130-179 mmHg or diastolic 80-109 mmHg\n4. Taking antihypertensive medication\n5. Able to understand and communicate in Turkish\n6. Willing to provide written informed consent\n\nExclusion Criteria:\n\n1. Secondary hypertension\n2. Pregnancy or lactation\n3. Severe cardiovascular disease (heart failure, myocardial infarction within 6 months)\n4. Stroke history within 6 months\n5. Skin lesions or infection at acupressure sites (HT7, LI4, PC6, EX3)\n6. Peripheral neuropathy affecting sensation\n7. Current use of anticoagulant therapy\n8. Participation in another clinical trial within 30 days","ALL","18 Years","65 Years",{"count":21,"type":22},72,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized controlled trial examines the effects of nurse-led self-acupressure at HT7, LI4, PC6, and EX3 points on blood pressure, stress, and well-being in adults with primary hypertension. Participants are randomized to real acupressure, sham acupressure, or usual care groups for 2 weeks.",[28],"PRIMARY HYPERTENSION",[30],"Acupressure Hypertension Self-care Nursing Stress Well-being Randomized Controlled Trial","NOT_YET_RECRUITING","2026-05-12",{"date":34,"type":35},"2026-05-14","ACTUAL",{"date":37,"type":22},"2026-06",{"date":39,"type":22},"2026-10",{"name":41,"class":42},"Abant Izzet Baysal University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":43},"100611095","dietary-nitrate-and-the-oral-microbiome-in-children-with-primary-hypertension-100611095","NCT07236125","Dietary Nitrate and the Oral Microbiome in Children With Primary Hypertension","Investigation of the Relationship Between Dietary Nitrate and Oral Microbiota in Children With Primary Hypertension","Inclusion Criteria:\n\n* Applied to the Istanbul University Faculty of Medicine, Department of Pediatric Nephrology,\n* Between the ages of 10 and 18,\n* Diagnosed with primary hypertension,\n* Clinically excluded from secondary hypertension or heart failure,\n* No systemic or chronic disease other than hypertension,\n* No periodontal disease, dental infection, or oral mucosal disease,\n* Not taking regular antihypertensive or other medications for a chronic disease,\n* Not having received antibiotic treatment in the last 3 months,\n* Patients who have not used mouthwash in the last 3 months,\n* Have no allergies to nitrate-rich foods,\n* Both male and female patients will be included.\n\nExclusion Criteria:\n\n* Younger than 10 years of age or older than 18 years of age\n* Clinically diagnosed with secondary hypertension or heart failure\n* Have a systemic disease\n* Have periodontal disease, dental infection, or oral mucosal disease\n* Are taking regular antihypertensive medications or other chronic illnesses\n* Have received antibiotic treatment within the last 3 months\n* Have used mouthwash within the last 3 months\n* Are allergic to nitrate-rich foods will not be included in the study.",true,"10 Years",{"count":54,"type":22},48,"1 Day","OBSERVATIONAL","Children and adolescents with primary hypertension (high blood pressure without an underlying secondary cause) are at increased risk of cardiovascular disease in adulthood. Recent research suggests that not only the heart and blood vessels, but also the bacteria living in the mouth may play a role in blood pressure regulation. Certain oral bacteria can convert nitrate from food into nitrite and then into nitric oxide, a substance that helps blood vessels relax. If this nitrate-nitrite-nitric oxide pathway is impaired, blood pressure may rise.\n\nThis study aims to investigate the relationship between oral microbiota, salivary nitric oxide reductase activity and blood pressure in children and adolescents with primary hypertension compared with healthy peers. We will recruit participants aged 10-18 years who have a diagnosis of primary hypertension and an age- and sex-matched control group without hypertension.\n\nAll participants will undergo a non-invasive oral and dental examination and standardized blood pressure measurements. Saliva samples will be collected to measure pH, flow rate, nitrate and nitrite levels, total protein, lysozyme activity and to analyze the composition of oral bacteria using modern DNA-based techniques. Participants and\u002For their parents will also complete brief questionnaires about diet and general health.\n\nNo medication or dietary supplement will be given as part of the study, and no additional blood samples will be taken beyond routine clinical care. The main risk is minimal discomfort related to oral examination and saliva collection. There is no guaranteed direct benefit for participants; however, the results may help us better understand how oral bacteria and salivary nitric oxide pathways are linked to high blood pressure in young people. This knowledge may support the development of new non-invasive strategies for early detection and prevention of hypertension in the future.",[59],"Primary Hypertension",[61,62,63,64,65,66,67,68,69,70,71,72,73,74,75],"primary hypertension","oral microbiome","nitrate-reduction bacteria","salivary nitrite","salivary nitrate","pediatric hypertension","Enterosalivary Nitrate Cycle","Adolescent Hypertension","Salivary Microbiome","Nitrate-Nitrite-Nitric Oxide Pathway","Saliva Biomarkers","Endothelial Dysfunction","Blood Pressure in Adolescents","Non-invasive Biomarkers","Saliva-Based Diagnostics","RECRUITING","2026-05-04",{"date":79,"type":35},"2026-05-08",{"date":81,"type":35},"2026-04-15",{"date":83,"type":22},"2027-01-15",{"name":85,"class":42},"Yelda Kasımoğlu",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":43},"100636512","high-intensity-transcranial-alternating-current-stimulation-hi-tacs-for-hypertension-a-randomized-controlled-trial-100636512","NCT07566650","High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) for Hypertension: A Randomized Controlled Trial","A Randomized Controlled Trial of High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) for the Treatment of Essential Hypertension","Inclusion Criteria:\n\n* Clinical diagnosis of primary hypertension (Grade 1-3) as defined by the Chinese Hypertension Guidelines (Revised Edition 2024).\n* For females of childbearing potential, agreement to use contraception during the study.\n* Willing and able to comply with study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Women who are pregnant, breastfeeding, or planning pregnancy during the study period.\n* Resistant hypertension (blood pressure uncontrolled despite adherence to ≥3 antihypertensive drugs of different classes at optimal doses, including a diuretic ), or known secondary hypertension.\n* History of severe cardiovascular or cerebrovascular disease (e.g., myocardial infarction, stroke, heart failure NYHA Class III-IV) within the past 6 months, or severe hepatic or renal dysfunction (defined as ALT\u002FAST \\>3× upper limit of normal \\[ULN\\], or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n* Uncontrolled sleep apnea syndrome, active infectious diseases, chronic wasting diseases, or significant cognitive impairment.\n* Current major psychiatric disorder as assessed by the Mini-International Neuropsychiatric Interview (M.I.N.I.).\n* Contraindications to tACS or MRI: implanted electronic devices, intracranial metal implants, or known history of seizures.\n* Skin lesions, eczema, or broken skin at the intended electrode placement sites.\n* Participation in another clinical trial involving an investigational product or device within 30 days prior to screening.\n* Any condition that, in the opinion of the investigator, would jeopardize the patient's safety or compliance with the study protocol, or interfere with data interpretation.",{"count":94,"type":22},50,[25],"This study focuses on individuals with primary hypertension, with the main objective of investigating the effectiveness and safety of high-intensity transcranial alternating current stimulation (Hi-tACS) as a non-invasive, non-pharmacological treatment for hypertension",[59],[99,100,101,61],"transcranial alternating current stimulation","autonomic nervous system","neuromodulation","2026-04-29",{"date":104,"type":35},"2026-05-05",{"date":106,"type":22},"2026-05-01",{"date":108,"type":22},"2028-05-01",{"name":110,"class":42},"Xuanwu Hospital, Beijing",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":43},"100630344","phase-1-bioequivalence-study-of-sacubitril-alisartan-amlodipine-tablets-100630344","NCT07486453","Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets","Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets Versus Sacubitril Alisartan Calcium Tablets Combined With Amlodipine Besylate Tablets","Inclusion Criteria:\n\n* Study participants aged 18 to 60 years (inclusive of 18 and 60 years), both male and female\n* Body weight not less than 50 kg. Body Mass Index (BMI) = weight (kg) \u002F height\\^2 (m\\^2). BMI must be within the range of 19 to 26 kg\u002Fm\\^2 (inclusive of the limit values)\n* The study participant is able to communicate well with the research staff, fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial, and sign a written informed consent form\n* The study participant or their partner has no plans for pregnancy, sperm donation, or egg donation during the study period and for 3 months after drug administration, and must agree to use at least one acceptable effective contraceptive method\n* During the screening period: 110 mmHg ≤ seated systolic blood pressure (SBP) \\\u003C 140 mmHg, 65 mmHg ≤ seated diastolic blood pressure (DBP) \\\u003C 90 mmHg, and no orthostatic hypotension.\n\nExclusion Criteria:\n\n* Those who smoked more than 5 cigarettes per day on average in the 3 months prior to the trial and are unable to quit smoking during the trial period.\n* Pregnant or breastfeeding women, or female study participants of childbearing potential with a positive blood pregnancy screening.\n* Known allergic reaction to angiotensin II receptor antagonists (such as sacubitril\u002Fvalsartan sodium, alisartan ester, losartan, valsartan) and calcium channel blockers (such as nifedipine, amlodipine), or their excipients; or allergic constitution (multiple drug and food allergies).\n* Alcoholics or those who frequently consumed alcohol within the 3 months prior to screening, i.e., consuming more than 14 standard alcohol units per week (1 unit alcohol = 360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine), or those with a positive alcohol breath test, or those unable to stop using any alcohol-containing products during the trial period.\n* Those who donated blood or experienced significant blood loss (\\>400 mL), used blood products, or received a blood transfusion within the three months prior to screening.\n* Those who have undergone surgery within 3 months prior to screening or plan to undergo surgery during the study period, or subjects with a history of surgery affecting drug absorption, distribution, metabolism, or excretion.\n* Those who have been vaccinated within 3 months prior to screening.\n* History of hypotension, syncope, needle fainting, swallowing difficulties, any gastrointestinal disease affecting drug absorption, or any history of conditions increasing hemorrhagic risk, such as acute gastritis or gastroduodenal ulcers.\n* Use of any drug that alters hepatic enzyme (CYP3A4) activity or inhibitors of transporters (OAT1\u002F3, OATP1B1\u002F3) within 28 days prior to screening.\n* Use of any prescription drugs, over-the-counter medications, vitamin products, or herbal remedies within 14 days prior to screening.\n* Participation in any drug clinical trial and administration of any other investigational drug, or use of investigational products, within 3 months prior to taking the study drug.\n* Clinically significant abnormalities in vital signs, physical examination, 12-lead electrocardiogram (ECG), or laboratory tests (including complete blood count, urinalysis, blood biochemistry, coagulation profile, and four infectious disease markers) at screening.\n* Any other disease or medical history considered by the investigator as unsuitable for participation in this study, such as disorders of the central nervous, cardiovascular, digestive, respiratory, urinary, hematopoietic, immune systems, psychiatric conditions, or metabolic abnormalities.\n* Consumption of chocolate, any caffeine-containing, or xanthine-rich foods or beverages within 48 hours prior to taking the study drug.\n* History of drug abuse or substance abuse, or a positive urine drug screen at screening.\n* Those with special dietary habits who cannot comply with the unified dietary requirements, or those with lactose intolerance (e.g., history of diarrhea after drinking milk).\n* Any other reason considered by the investigator as unsuitable for enrollment.","60 Years",{"count":120,"type":22},60,[122],"PHASE1","This study aims to evaluate the bioequivalence and safety of single oral administration of Sacubitril\u002FValsartan\u002FAmlodipine Tablets (240mg\u002F5mg) versus Sacubitril\u002FValsartan Calcium Tablets (240mg) combined with Amlodipine Besylate Tablets (5mg) in healthy adult study participants.",[59],"2026-03-18",{"date":127,"type":35},"2026-03-20",{"date":129,"type":22},"2026-03-09",{"date":131,"type":22},"2026-04-25",{"name":133,"class":134},"Shenzhen Salubris Pharmaceuticals Co., Ltd.","INDUSTRY",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":43},"100607763","the-effect-of-lavender-inhalation-on-anxiety-sleep-and-blood-pressure-100607763","NCT07192783","The Effect of Lavender Inhalation on Anxiety, Sleep, and Blood Pressure","Effects of Lavender Oil Inhalation Applied to Patients With Primary Hypertension on Anxiety, Sleep Quality and Blood Pressure","Inclusion Criteria:\n\n* Diagnosed with primary hypertension\n* Willing to participate in the study\n* No allergy to lavender\n* No olfactory impairments\n* No history of psychiatric disorders\n\nExclusion Criteria:\n\n* Communication difficulties\n* Unwilling to participate\n* Using other herbal or aromatherapy treatments\n* History of sleep disorders affecting sleep quality (e.g., obstructive sleep apnea)\n* Secondary hypertension or other chronic diseases\n* Pregnant or breastfeeding\n* Use of tobacco products",{"count":94,"type":22},[25],"This study aims to determine the effects of lavender oil inhalation on anxiety, sleep quality, and blood pressure in patients with primary hypertension. The study is designed as a double-blind randomized controlled trial. The study population consists of patients presenting to the Cardiology Outpatient Clinic of Ardahan State Hospital. Participants are randomly assigned to an experimental group, which will receive a total of 12 lavender oil inhalations three times a week for one month, or to a control group, which will continue routine treatment and care. Data will be collected using the Hypertension Diagnostic Form, Beck Anxiety Inventory, and Pittsburgh Sleep Quality Index. Statistical analyses will be conducted to compare outcomes between the experimental and control groups.",[59],[61,147,148,149],"anxiety","sleep quality","blood pressure","2025-09-17",{"date":152,"type":35},"2025-09-25",{"date":154,"type":35},"2025-07-07",{"date":156,"type":22},"2025-10-09",{"name":158,"class":42},"Ardahan University",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100587541","automatic-and-conventional-methods-of-hypertensive-patients-monitoring-100587541","NCT06929728","Automatic and Conventional Methods of Hypertensive Patients Monitoring","Copmaring Automatic Blood Preesure Measurments To Conventional Office Readings For Monitoring Hypertensive Patients And Predicting Hypertention Mediated Organ Damage","Inclusion Criteria:\n\n* Patients who were screening for suspected hypertention or white coat hypertention .\n* medically underserved population .\n* primary arterial hypertention .\n* high risk hypertensive patients \\[resistant hypertension ,patients with poor medication adherance \\]\n\nExclusion Criteria:\n\n* patients with secondary causes of hypertention\n* patients with other cardiac diseases \\[heart faliure ,valvular heart diseases \\]\n* chronic illness affect blood pressure as chronic kideny disease .","70 Years",{"count":168,"type":22},620,"comparing automatic blood pressure measurments methods with conventional office methods in follow up and monitoring of hypertensive patients and predicting hypertension mediated organ damage .",[59],[172],"HTN , HMOD ,BP , LVH ,LAE","2025-04-08",{"date":175,"type":35},"2025-04-16",{"date":177,"type":22},"2025-10",{"date":179,"type":22},"2026-12",{"name":181,"class":42},"Assiut University",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":202,"locationsCount":43},"100509733","phase-4-multi-omics-to-predict-the-blood-pressure-response-to-antihypertensives-100509733","NCT05917275","Multi-Omics to Predict the Blood Pressure Response to Antihypertensives","HT-PREDICT","Inclusion criteria\n\n* Age 18 up to and including 75 years\n* 24 hours systolic blood pressure 130-164 (corresponding with grade 1-2 hypertension), without the use of blood pressure lowering agents (at screening for patients without pre-treatment or after 4 week wash-out of antihypertensive medication for subjects using a single antihypertensive agent at screening)\n* Indication for antihypertensive therapy according to the 2023 European Society of Hypertension Guidelines for the management of arterial hypertension\n* Subject is not treated with antihypertensive drugs or is treated with a single antihypertensive drug.\n* Female patients must be non-lactating and at no risk of pregnancy for one of the following reasons: 1 year postmenopausal, surgically sterile, or willing to use an acceptable method of contraception (oral contraceptives, approved contraceptive implants, long-term injectable contraception, intrauterine devices, or tubal ligation are allowed.)\n\nExclusion criteria\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Treatment with 2 or more antihypertensive drugs \\\u003C 3 months before inclusion. It is not allowed to stop medication for study purposes in subjects treated with 2 or more anti-hypertensive drugs.\n* Known diagnosis of secondary hypertension to an identifiable cause other than treated sleep apnea (e.g., hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome, coarctation of the aorta, uncontrolled hyper- or hypothyroidism and intracranial tumor)\n* Use of VEGF inhibitors, calcineurin inhibitors, glucocorticosteroids, erythropoietin stimulation agents, daily use of NSAID's\n* Use of MDMA, methamphetamine, cocaine\n* Use of glycyrrhetinic acid containing products , i.e. liquorice, specific herbal teas, \\\u003C4 weeks before inclusion. (If patients are willing to stop the intake of glycyrrhetinic acid containing products for the duration of the trial, they can be rescreened after 4 weeks of stopping glycyrrhetinic acid containing products)\n* Use of potassium containing supplements\n* Concurrent use of medication or a supplement with significant drug interaction with study medication. Special attention is warranted for amlodipine which is metabolized by Cyp3A4. Subjects using strong inhibitors or inducers of Cyp3A4 are excluded from participation in this trial. A list of strong inhibitors and inducers is provided in Addendum 1 of this protocol. For information on possible drug interactions we refer to the website of Lexi-Interact Online (Lexicomp® Drug Interactions - UpToDate (doctorabad.com): https:\u002F\u002Fdoctorabad.com\u002FUpToDate\u002Fd\u002Fdi.htm).\n* History of myocardial infarction, angina pectoris\n* History of atrial fibrillation\n* History of severe valvular or structural heart disease (excluding left ventricular hypertrophy)\n* History of NYHA class III or IV heart failure or known reduced left ventricular function (ejection fraction (EF) \\\u003C30%)\n* History of cerebrovascular accident or transient ischemic attack\n* History of hypertensive crisis\n* History of liver failure\n* History of skin cancer\n* History of gout\n* Current hyperparathyroidism\n* Current biliary tract obstruction\n* Pregnancy\n* Life expectancy \\\u003C 1 year\n* Known side effect or contra-indication to treatment with calcium channel blockers\n* Known side effect or contra-indication to treatment with angiotensin II receptor blockers\n* Known side effect or contra-indication to treatment with thiazide diuretics\n* Arm circumference \\> 46 cm\n* Sodium level outside reference range at screening visit\n* Potassium level outside reference range at screening visit\n* Calcium level outside reference range at screening visit\n* eGFR \\\u003C 50 ml\u002Fmin\u002F1,73m2\n* Use of loop diuretics.","75 Years",{"count":191,"type":22},96,[193],"PHASE4","The goal of this clinical trial is to develop biomarkers composed of multiple OMICs (MOMICs) for prediction of blood pressure response to antihypertensive drugs in the treatment of primary hypertension. The main objectives are:\n\n* Primary objective:\n\n  \\- To identify MOMICs biomarkers that predict the response in 24-hour blood pressure to antihypertensive treatment for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan\u002Famlodipine)\n* Secondary objectives:\n\n  * To identify a MOMICs biomarker that predict the response in night-time blood pressure to anti-hypertensive treatment for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan\u002Famlodipine)\n  * To identify MOMICs biomarkers that predict side effects, including changes in QoLof olmesartan, amlodipine and hydrochlorothiazide.\n* Exploratory objective:\n\n  * To assess changes in MOMICs biomarkers induced by each drug\n\nParticipants will undergo three 4-week treatment periods:\n\n* Each subject receives 3 out of 4 possible treatments (olmesartan, amlodipine, hydrochlorothiazide, olmesartan\u002Famlodipine).\n* Before and after each treatment period OMICS measurements and an ABPM are performed.\n* At the end of each treatment period blood is sampled for drug level testing to assess adherence.\n* Electrolytes and kidney function are checked 5-7 days after start of each treatment period.",[59],"2024-06-07",{"date":198,"type":35},"2024-06-10",{"date":200,"type":35},"2024-04-04",{"date":177,"type":22},{"name":203,"class":42},"Radboud University Medical Center",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":189,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":43},"100525024","the-safety-and-efficacy-of-carotid-body-modulation-therapy-in-hypertensive-patients-by-external-ultrasonic-micro-bubble-100525024","NCT06116357","The Safety and Efficacy of Carotid Body Modulation Therapy in Hypertensive Patients by External Ultrasonic Micro-bubble","Inclusion Criteria:\n\n* Hypertensive patients for CB modulation therapy\n\n  1. Two or more antihypertensive medications that had been prescribed at least 50% of the manufacturer's maximum dose for at least 2 consecutive weeks before study; Patients take an angiotensin-converting enzyme inhibitor (ACEI) (or angiotensin-ⅱ receptor antagonist (ARB)) and calcium channel blocker (CCB) (or thiazide diuretic) ; Office systolic blood pressure (SBP)≥150 mmHg and \\\u003C180mmHg.\n\n     2.24-hour ambulatory systolic blood pressure: ≥135 mmHg and \\\u003C170 mmHg\n\n  3.A history of primary hypertension was recorded. 4.Patients who can understand the purpose of the trial, voluntarily participate and sign informed consent, and are willing to cooperate with clinical follow-up\n* Patients for CB Volume and activity evaluation Hypertension group\n\n  1. Primary hypertension patients agrees to take part in this study and perform CB MRI, ultrasound, CB activity tests and sign the informed consent.\n  2. The office blood pressure of patients ≥ 140\u002F90 mmHg; the patents were diagnosed hypertension and are taking anti-hypertensive drugs could also include, although the office blood pressure \\\u003C 140\u002F90 mmHg.\n  3. The CB could be detected by carotid ultrasound or MRI. Control group\n\n  \u003C!-- -->\n\n  1. The volunteers agree to take part in this study and perform CB MRI, ultrasound, CB activity tests and sign the informed consent.\n  2. The volunteers are healthy.\n\nExclusion Criteria:\n\n* Hypertensive patients for CB modulation therapy\n\n  1. Carotid body anatomy is not eligible for treatment: ultrasound examination before treatment fail to find carotid body at carotid artery bifurcation.\n  2. Carotid body anatomical heterotopic is difficult to select or unsuitable for ultrasound irradiation.\n  3. Carotid anatomy that does not meet treatment conditions: severe carotid stenosis or occlusion.\n  4. Carotid ulcer.\n  5. Severe tortuosity of carotid artery\n  6. After carotid artery stenting or stripping\n  7. Other conditions that are not suitable for carotid intervention\n  8. Glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin \u002F 1.73 m2\n  9. Have type 1 diabetes or poorly controlled type 2 diabetes (defined as plasma HbA1c≥ 9.0% or 24-hour urinary protein quantity \\>1g\u002F24h or proliferative retinal lesions)\n  10. postural hypotension.\n  11. Recent vascular events: Experienced acute myocardial infarction, unstable angina, syncope, or cerebrovascular accident within 3 months of the screening period.\n  12. Suspected secondary hypertension.\n  13. Respiratory support: The individual requires long-term oxygen support or mechanical ventilation (except for nighttime breathing support only because of sleep apnea).\n  14. Life expectancy \\\u003C1 year.\n  15. A woman who is pregnant, breastfeeding, or planning to become pregnant.\n  16. Subjects who are currently enrolled in another clinical trial and have not completed the primary endpoint.\n  17. Allergic to contrast media.\n  18. The investigators judged the patients' poor compliance and other reasons for not being suitable for participants in the trial.\n  19. Any other conditions that the investigator did not consider appropriate to participate in the trial.\n* Patients for CB Volume and activity evaluation\n\n  1. the CB could not be detected by carotid ultrasound or MRI.\n  2. The patients have secondary hypertension, heart failure.\n  3. The patients have type 1diabetes mellitus, CB tumor.\n  4. The patients were diagnosed as OSAS.\n  5. The patients have severe chronic constructive pulmonary disease, interstitial lung disease or other severe lung diseases.\n  6. Women who are pregnant, breastfeeding, or planning to become pregnant.\n  7. Patients with other conditions which are not appropriate for enrollment judged by the investigators.",{"count":211,"type":22},200,[25],"The investigators intend to find a noninvasive method for CB modulation therapy and find a simple and convenient indicator for assessing CB activity. This study was designed to evaluate the safety and efficacy of carotid body modulation therapy in hypertensive patients by external ultrasonic micro-bubble and also identify the association between CB volume and CB activity.",[59],[216,217,218,219,220],"Carotid body modulation therapy","Hypertension","Carotid body activity","Carotid body volume","Ultrasonic micro-bubble","2023-10-30",{"date":223,"type":35},"2023-11-03",{"date":225,"type":22},"2023-12-01",{"date":227,"type":22},"2026-12-30",{"name":229,"class":42},"Jing Huang"]